Expertise in
1
conditions

Degang G. Ding

No. 7 Weiwu Road, 
Zhengzhou, CN 
Expertise in
1
conditions
No. 7 Weiwu Road, 
Zhengzhou, CN 

Overview

Degang Ding practices practicing medicine in Zhengzhou, China.

Ding is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Bladder Cancer, Renal Cell Carcinoma (RCC), Upper Tract Urothelial Carcinoma (UTUC), Tissue Biopsy, and Nephrectomy.

They are actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 7 Weiwu Road, Zhengzhou, 450003, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
View 1 Less Clinical Trial

40 Total Publications

DERL3 Predicts and Drives Acquired Sunitinib Resistance in Renal Cell Carcinoma by Suppressing ER Stress-ROS-Dependent Apoptosis.
DERL3 Predicts and Drives Acquired Sunitinib Resistance in Renal Cell Carcinoma by Suppressing ER Stress-ROS-Dependent Apoptosis.
Journal: Biomedicines
Published: July 01, 2026

Frequently Asked Questions about Degang G. Ding

Is Degang G. Ding a top-rated expert for Tissue Biopsy?

MediFind is an objective health platform that identifies experts based on real-world data. Degang G. Ding is classified as an Advanced expert for Tissue Biopsy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Degang G. Ding participate in research or clinical trials?

Yes. Degang G. Ding has published 40 articles and abstracts on conditions like Tissue Biopsy. You can view a list of Degang G. Ding's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ding's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile